Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: further exploring the role of P53 and WT1 gene

References

• Cheung M M, Chan J K, Lau W H, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70–77
   PubMed Web of Science ®Google Scholar
• Kwong Y L, Chan A C, Liang R, et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821–829
   PubMed Web of Science ®Google Scholar
• Liang R, Todd D, Chan T K, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995; 13: 666–670
   PubMed Web of Science ®Google Scholar
• Kang Y K, Zhan Z, Regis J, et al. Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 1995; 86: 1515–1524
   PubMed Web of Science ®Google Scholar
• Zhan Z, Sandor V A, Gamelin E, et al. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood 1997; 89: 3795–3800
   PubMed Web of Science ®Google Scholar
• Cheng A L, Su I J, Chen Y C, et al. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993; 11: 109–115
   PubMed Web of Science ®Google Scholar
• Ross D D. Novel mechanisms of drug resistance in leukemia. Leukemia 2000; 14: 467–473
   PubMed Web of Science ®Google Scholar
• Cho E Y, Gong G, Khang S K, et al. Fine needle aspiration cytology of CD56-positive natural killer/T-cell lymphoma of soft tissue. Cancer 2002; 96: 344–350
   PubMed Web of Science ®Google Scholar
• Cole S P, Bhardwaj G, Gerlach J H, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650–1654
   PubMed Web of Science ®Google Scholar
• Izquierdo M A, Shoemaker R H, Flens M J, et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996; 65: 230–237
   PubMed Web of Science ®Google Scholar
• Filipits M, Drach J, Pohl G, et al. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 1999; 5: 2426–2430
   PubMed Web of Science ®Google Scholar
• List A F, Spier C S, Grogan T M, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464–2469
   PubMed Web of Science ®Google Scholar
• Filipits M, Pohl G, Stranzl T, et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91: 1508–1513
   PubMed Web of Science ®Google Scholar
• Borg A G, Burgess R, Green L M, et al. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998; 103: 1083–1091
   PubMed Web of Science ®Google Scholar
• den Boer M L, Pieters R, Kazemier K M, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092–2098
   PubMed Web of Science ®Google Scholar
• Ohno N, Tani A, Uozumi K, et al. Expression of functional lung resistance–related protein predicts poor outcome in adult T-cell leukemia. Blood 2001; 98: 1160–1165
   PubMed Web of Science ®Google Scholar
• Chen W, Cooper N R. Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity. J Virol 1996; 70: 4849–4853
   PubMed Web of Science ®Google Scholar
• Kim G EYW, Lee S W, Rha S Y, et al. Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leuk Lymphoma 2004; 45: 1857–1864
   PubMed Web of Science ®Google Scholar
• Oka M, Kounoura K, Narasaki F, et al. P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res 1997; 88: 738–742
   PubMedGoogle Scholar
• Drakos E RG, Tsioli P, Lai R, et al. Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem Mol Morphol 2005; 13: 132–137
   PubMedGoogle Scholar
• Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002; 19: 87–104
   PubMed Web of Science ®Google Scholar
• Ohsawa M IY, Fukushima H, Shirai N, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005; 68: 422–431
   PubMed Web of Science ®Google Scholar
• Chin K V, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459–462
   PubMed Web of Science ®Google Scholar
• Wang Q, Beck W T. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 1998; 58: 5762–5769
   PubMed Web of Science ®Google Scholar
• Li T, Hongyo T, Syaifudin M, et al. Mutations of the p53 gene in nasal NK/T-cell lymphoma. Lab Invest 2000; 80: 493–499
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Franklin J L, Guerrero I, et al. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. Hum Pathol 1999; 30: 849–855
   PubMed Web of Science ®Google Scholar
• Takahara M, Kishibe K, Bandoh N, et al. P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol 2004; 35: 86–95
   PubMed Web of Science ®Google Scholar
• Szekely L, Pokrovskaja K, Jiang W Q, et al. Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their Rb, p53 and EBNA-5 expression patterns. Oncogene 1995; 10: 1869–1874
   PubMed Web of Science ®Google Scholar
• Gulley M L, Burton M P, Allred D C, et al. Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. Hum Pathol 1998; 29: 252–259
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405–1412
   PubMed Web of Science ®Google Scholar
• Menke A L, Clarke A R, Leitch A, et al. Genetic interactions between the Wilms' tumor 1 gene and the p53 gene. Cancer Res 2002; 62: 6615–6620
   PubMed Web of Science ®Google Scholar
• Elisseeva O A, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272–3279
   PubMed Web of Science ®Google Scholar